Marine-derived microbes and molecules for drug discovery

Abstract Increasing attention has been paid to marine-derived biomolecules as sources of therapeutics for autoimmune diseases. Nagasaki Prefecture has many islands and is surrounded by seas, straits, gulfs, bays, and coves, giving it the second longest coastline in Japan after Hokkaido. We have coll...

Full description

Bibliographic Details
Main Authors: Yoshimasa Tanaka, Megumi Nishikawa, Kaho Kamisaki, Saki Hachiya, Moeka Nakamura, Takahiro Kuwazuru, Susumu Tanimura, Kiyoshi Soyano, Kohsuke Takeda
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Inflammation and Regeneration
Subjects:
Online Access:https://doi.org/10.1186/s41232-022-00207-9
_version_ 1817968763414249472
author Yoshimasa Tanaka
Megumi Nishikawa
Kaho Kamisaki
Saki Hachiya
Moeka Nakamura
Takahiro Kuwazuru
Susumu Tanimura
Kiyoshi Soyano
Kohsuke Takeda
author_facet Yoshimasa Tanaka
Megumi Nishikawa
Kaho Kamisaki
Saki Hachiya
Moeka Nakamura
Takahiro Kuwazuru
Susumu Tanimura
Kiyoshi Soyano
Kohsuke Takeda
author_sort Yoshimasa Tanaka
collection DOAJ
description Abstract Increasing attention has been paid to marine-derived biomolecules as sources of therapeutics for autoimmune diseases. Nagasaki Prefecture has many islands and is surrounded by seas, straits, gulfs, bays, and coves, giving it the second longest coastline in Japan after Hokkaido. We have collected more than 20,000 marine microbes and have been preparing an original marine microbial extract library, which contains small and mid-size biomolecules that may penetrate cell membranes and interfere with the intracellular protein–protein interaction involved in the development of autoinflammatory diseases such as familial Mediterranean fever. In addition, we have been developing an indoor shark farming system to prepare shark nanobodies that could be developed as potential therapeutic agents for autoimmune diseases. Sharks produce heavy-chain antibodies, called immunoglobulin new antigen receptors (IgNARs), consisting of one variable domain (VNAR) and five constant domains (CNAR); of these, VNAR can recognize a variety of foreign antigens. A VNAR single domain fragment, called a nanobody, can be expressed in Escherichia coli and has the properties of an ideal therapeutic candidate for autoimmune diseases. Shark nanobodies contain complementarity-determining regions that are formed through the somatic rearrangement of variable, diversity, and joining segments, with the segment end trimming and the N- and P-additions, as found in the variable domains of mammalian antibodies. The affinity and diversity of shark nanobodies are thus expected to be comparable to those of mammalian antibodies. In addition, shark nanobodies are physically robust and can be prepared inexpensively; as such, they may lead to the development of highly specific, stable, effective, and inexpensive biotherapeutics in the future. In this review, we first summarize the history of the development of conventional small molecule drugs and monoclonal antibody therapeutics for autoimmune diseases, and then introduce our drug discovery system at Nagasaki University, including the preparation of an original marine microbial extract library and the development of shark nanobodies.
first_indexed 2024-04-13T20:12:09Z
format Article
id doaj.art-c5173ffe1e174398bc8f7647c6db1483
institution Directory Open Access Journal
issn 1880-8190
language English
last_indexed 2024-04-13T20:12:09Z
publishDate 2022-06-01
publisher BMC
record_format Article
series Inflammation and Regeneration
spelling doaj.art-c5173ffe1e174398bc8f7647c6db14832022-12-22T02:31:48ZengBMCInflammation and Regeneration1880-81902022-06-0142111210.1186/s41232-022-00207-9Marine-derived microbes and molecules for drug discoveryYoshimasa Tanaka0Megumi Nishikawa1Kaho Kamisaki2Saki Hachiya3Moeka Nakamura4Takahiro Kuwazuru5Susumu Tanimura6Kiyoshi Soyano7Kohsuke Takeda8Center for Medical Innovation, Nagasaki UniversityDepartment of Cell Regulation, Graduate School of Biomedical Sciences, Nagasaki UniversityDepartment of Cell Regulation, Graduate School of Biomedical Sciences, Nagasaki UniversityDepartment of Cell Regulation, Graduate School of Biomedical Sciences, Nagasaki UniversityDepartment of Cell Regulation, Graduate School of Biomedical Sciences, Nagasaki UniversityInstitute for East China Sea Research, Nagasaki UniversityDepartment of Cell Regulation, Graduate School of Biomedical Sciences, Nagasaki UniversityInstitute for East China Sea Research, Nagasaki UniversityDepartment of Cell Regulation, Graduate School of Biomedical Sciences, Nagasaki UniversityAbstract Increasing attention has been paid to marine-derived biomolecules as sources of therapeutics for autoimmune diseases. Nagasaki Prefecture has many islands and is surrounded by seas, straits, gulfs, bays, and coves, giving it the second longest coastline in Japan after Hokkaido. We have collected more than 20,000 marine microbes and have been preparing an original marine microbial extract library, which contains small and mid-size biomolecules that may penetrate cell membranes and interfere with the intracellular protein–protein interaction involved in the development of autoinflammatory diseases such as familial Mediterranean fever. In addition, we have been developing an indoor shark farming system to prepare shark nanobodies that could be developed as potential therapeutic agents for autoimmune diseases. Sharks produce heavy-chain antibodies, called immunoglobulin new antigen receptors (IgNARs), consisting of one variable domain (VNAR) and five constant domains (CNAR); of these, VNAR can recognize a variety of foreign antigens. A VNAR single domain fragment, called a nanobody, can be expressed in Escherichia coli and has the properties of an ideal therapeutic candidate for autoimmune diseases. Shark nanobodies contain complementarity-determining regions that are formed through the somatic rearrangement of variable, diversity, and joining segments, with the segment end trimming and the N- and P-additions, as found in the variable domains of mammalian antibodies. The affinity and diversity of shark nanobodies are thus expected to be comparable to those of mammalian antibodies. In addition, shark nanobodies are physically robust and can be prepared inexpensively; as such, they may lead to the development of highly specific, stable, effective, and inexpensive biotherapeutics in the future. In this review, we first summarize the history of the development of conventional small molecule drugs and monoclonal antibody therapeutics for autoimmune diseases, and then introduce our drug discovery system at Nagasaki University, including the preparation of an original marine microbial extract library and the development of shark nanobodies.https://doi.org/10.1186/s41232-022-00207-9Autoimmune diseaseAutoinflammatory diseaseBiologicConventional drugMarine microbeMonoclonal antibody
spellingShingle Yoshimasa Tanaka
Megumi Nishikawa
Kaho Kamisaki
Saki Hachiya
Moeka Nakamura
Takahiro Kuwazuru
Susumu Tanimura
Kiyoshi Soyano
Kohsuke Takeda
Marine-derived microbes and molecules for drug discovery
Inflammation and Regeneration
Autoimmune disease
Autoinflammatory disease
Biologic
Conventional drug
Marine microbe
Monoclonal antibody
title Marine-derived microbes and molecules for drug discovery
title_full Marine-derived microbes and molecules for drug discovery
title_fullStr Marine-derived microbes and molecules for drug discovery
title_full_unstemmed Marine-derived microbes and molecules for drug discovery
title_short Marine-derived microbes and molecules for drug discovery
title_sort marine derived microbes and molecules for drug discovery
topic Autoimmune disease
Autoinflammatory disease
Biologic
Conventional drug
Marine microbe
Monoclonal antibody
url https://doi.org/10.1186/s41232-022-00207-9
work_keys_str_mv AT yoshimasatanaka marinederivedmicrobesandmoleculesfordrugdiscovery
AT meguminishikawa marinederivedmicrobesandmoleculesfordrugdiscovery
AT kahokamisaki marinederivedmicrobesandmoleculesfordrugdiscovery
AT sakihachiya marinederivedmicrobesandmoleculesfordrugdiscovery
AT moekanakamura marinederivedmicrobesandmoleculesfordrugdiscovery
AT takahirokuwazuru marinederivedmicrobesandmoleculesfordrugdiscovery
AT susumutanimura marinederivedmicrobesandmoleculesfordrugdiscovery
AT kiyoshisoyano marinederivedmicrobesandmoleculesfordrugdiscovery
AT kohsuketakeda marinederivedmicrobesandmoleculesfordrugdiscovery